Objective: To pilot a method for determining whether homeopathically prepared mercury causes more symptoms (a "drug proving") in healthy volunteers than placebo.

Methods: One hundred and eighteen (118) healthy volunteers ages 18 to 65 were recruited by local advertising. Subjects unfamiliar with homeopathy undertook a 1-week single-blind placebo run-in, a 1-week of double-blind, randomized treatment on either homeopathically prepared mercury 12C or placebo, and a third week of placebo run-out. Each day, symptoms were recorded on a checklist that included both true mercury symptoms and symptoms not expected to be caused by mercury (false symptoms). Additional symptoms were assessed by open reporting. Outcome was assessed by calculating a score for each day as the number of true symptoms minus the number of false symptoms. The mean score during placebo was then subtracted from the mean score for weeks two and three of the trial.

Results: Fourteen (14) subjects dropped out during placebo run-in. The remaining 104 completed the trial. Baseline comparability was good. Mean difference score was -0.125 (SD 3.47) for mercury and -0.221 (SD 3.01) for placebo (p > 0.2). No significant differences between groups were found for the number of subjects meeting predefined criteria for a drug-proving reaction.

Conclusion: This pilot study failed to find evidence that mercury 12C causes significantly more symptoms in healthy volunteers than placebo. Questionnaires with a limited number of gross symptoms do not seem to be an appropriate methodological technique in drug proving research. If drug-proving phenomena exist, they appear to be rare.

Download full-text PDF

Source
http://dx.doi.org/10.1089/107555301750164208DOI Listing

Publication Analysis

Top Keywords

homeopathically prepared
12
prepared mercury
12
mercury symptoms
12
healthy volunteers
12
symptoms
11
symptoms healthy
8
placebo run-in
8
mercury 12c
8
false symptoms
8
mercury
7

Similar Publications

In the past 2-3 decades, numerous attempts have been made to create an insulin-secreting β cell line that maintains normal insulin secretion. However, primary β cell cultures have finite life and, therefore, cannot be used for long-term experiments. The most widely used insulin-secreting cell lines are Insulinoma-1, rat insulinoma cell line, hamster pancreatic β cell line, mouse insulinoma, and β tumor cell line.

View Article and Find Full Text PDF

Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model.

J Ayurveda Integr Med

December 2024

Anti-Cancer Drug Screening Facility (ACDSF), Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai-410210, India; Kode Lab, Tumor Immunology & Immunotherapy (TII) Group, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai-410210, India; Homi Bhabha National Institute (HBNI), Training School Complex, Anushakti Nagar, Mumbai 400094, India. Electronic address:

Background: Xenografts in immunodeficient mice play a pivotal role in testing novel anti-cancer treatments. Xenograft models expedite the drug discovery process, offering a cost-effective alternative to conventional animal models and providing essential data for clinical trials. We have followed the approach described by the Developmental Therapeutics Program of the National Cancer Institute (NCI), USA to investigate the therapeutic responses.

View Article and Find Full Text PDF

Introduction:  In 2020, a 26,849-ha state park in Mato Grosso do Sul state, Brazil, had 30% of its area damaged by fire. A homeopathic complex formulation was applied at strategic point locations in the park's springs or watercourses, aiming to mitigate the fire damage to the flora and fauna as quickly as possible. The duration of the homeopathic signal at each point was assessed using an established solvatochromic dye technique.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!